NOREPINEPHRINE BITARTRATE
| Brand name | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE |
|---|---|
| Active ingredient | NOREPINEPHRINE BITARTRATE |
| Strength | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | September 2022 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10888534 | April 2039 | product |
| RE49422 | February 2035 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.